NUCANA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.45 USD | -20.50% |
|
-24.58% | -39.82% |
Financials (USD)
| Sales 2024 * | - | Sales 2025 * | 750K | Capitalization | 11.72M |
|---|---|---|---|---|---|
| Net income 2024 * | -30M | Net income 2025 * | -32M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 15.6 x |
| P/E ratio 2024 * |
-0.44
x | P/E ratio 2025 * |
-0.44
x | Employees | 27 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.73% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | -10.67% | ||
| 1 week | -11.91% | ||
| Current month | -20.04% | ||
| 1 month | -40.38% | ||
| 3 months | -25.99% | ||
| 6 months | -64.64% | ||
| Current year | -29.72% |
1 week
0.19
0.24
1 month
0.190.38
Current year
0.190.78
1 year
0.190.96
3 years
0.194.62
5 years
0.1917.00
10 years
0.1932.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hugh Griffith
FOU | Founder | 56 | 97-01-27 |
Donald Munoz
DFI | Director of Finance/CFO | 56 | 15-09-30 |
Michelle Myers
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hugh Griffith
FOU | Founder | 56 | 97-01-27 |
Andrew Kay
CHM | Chairman | 69 | 20-12-20 |
Adam George
BRD | Director/Board Member | 54 | 18-04-03 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-15 | 4.45 | -20.50% | 32,225 |
| 24-04-12 | 5.598 | -5.37% | 10,498 |
| 24-04-11 | 5.915 | 0.00% | 5,732 |
| 24-04-10 | 5.915 | -0.34% | 9,096 |
| 24-04-09 | 5.935 | +0.59% | 12,333 |
Delayed Quote Nasdaq, April 15, 2024 at 11:09 am EDT
More quotes
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3â-deoxyadenosine (3â-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Companyâs subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.2239
USD
Average target price
4.793
USD
Spread / Average Target
+2,040.84%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.72% | 11.72M | |
| -1.64% | 102B | |
| +3.31% | 97.22B | |
| +4.25% | 22.27B | |
| -17.27% | 20.84B | |
| -4.50% | 19.19B | |
| -41.05% | 16.76B | |
| -22.36% | 14.76B | |
| +2.65% | 13.54B | |
| +24.55% | 11.53B |
- Stock Market
- Equities
- NCNA Stock
